Recro Pharma Acquires IRISYS (San Diego)

ABIONYX Pharma Acquires IRIS Pharma via Contribution in Kind

December 6, 2021

Biotechnology

ABIONYX Pharma completed a contribution in kind of 100% of the capital of IRIS Pharma Holding, issuing new ABIONYX shares at €3.60 per share to acquire the business. IRIS Pharma will become a subsidiary of ABIONYX while remaining operationally independent as a specialist CRO in ophthalmology, providing ABIONYX with ophthalmology R&D capabilities and a potential portfolio of biologic candidates.

Symeres Acquires DGr Pharma

September 15, 2025

Healthcare Services

Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.

Blue Wolf Capital Acquires Seven Recipharm OSD Sites and Agrees to Buy Synerlab to Create New CDMO Platform

April 2, 2024

Pharmaceuticals

Blue Wolf Capital Partners has agreed to acquire seven oral solid dosage (OSD) manufacturing and development facilities from Recipharm (located in Sweden, France and Spain) and has also agreed, subject to regulatory approvals, to acquire Synerlab, a Strasbourg-based CDMO. The transactions are intended to form a new independent CDMO platform (headquartered in the UK) that expands Blue Wolf's pharmaceutical manufacturing capabilities and commercial reach across Europe.

Topcon Healthcare Acquires Intelligent Retinal Imaging Systems (IRIS)

July 30, 2025

Medical Devices

Topcon Healthcare, the digital health and ocular data business of Topcon Corporation, has acquired Intelligent Retinal Imaging Systems (IRIS), a U.S.-based provider of cloud-based, AI-assisted retinal screening technology. The acquisition integrates IRIS into Topcon’s Harmony connected-care platform to expand retinal screening into primary care, strengthen PCP–ECP coordination, and accelerate early disease detection at scale.

Recipharm AB Acquires Vibalogics from Ampersand Capital Partners

February 18, 2022

Biotechnology

Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.

Azurity Pharmaceuticals Acquires Covis Pharma

March 14, 2025

Pharmaceuticals

Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.